Literature DB >> 24295806

Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses.

A T Newall1, J F Reyes2, J G Wood2, P McIntyre3, R Menzies3, P Beutels4.   

Abstract

Post-implementation evaluation should play an important role in assessing the success of public health programmes; however, the value for money achieved by vaccine programmes after introduction has received relatively little attention to date. In this article we explore the methodological challenges in these analyses and offer direction for future evaluations in the area. We identify alternative approaches to addressing these challenges, which include the estimation of disease changes attributable to vaccination efforts, the hypothetical no vaccination comparator scenario and the full benefit achieved by implemented vaccination programmes. We also outline other important considerations such as the evolution of prices over time. Further work needs to be done to explore these issues and to determine how the application of different approaches may impact on the results of evaluations in various circumstances. As retrospective analyses are likely to become more frequent and influential, it is important that both the benefits and the limitations of post-implementation evaluations are recognised and understood. We argue that it would be useful to establish a methodological framework to provide standards and guidance on how to undertake such analyses in the future.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Keywords:  Cost-effectiveness; Economic evaluation; Post-implementation; Programme evaluation; Retrospective; Vaccination

Mesh:

Year:  2013        PMID: 24295806     DOI: 10.1016/j.vaccine.2013.11.067

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  What do we know about the cost-effectiveness of pneumococcal conjugate vaccination in older adults?

Authors:  A T Newall
Journal:  Hum Vaccin Immunother       Date:  2016-07-11       Impact factor: 3.452

2.  Economic Evaluation of Vaccination Programmes in Older Adults and the Elderly: Important Issues and Challenges.

Authors:  Sevan Dirmesropian; James G Wood; C Raina MacIntyre; Philippe Beutels; Anthony T Newall
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

3.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Authors:  Bernhard Ultsch; Oliver Damm; Philippe Beutels; Joke Bilcke; Bernd Brüggenjürgen; Andreas Gerber-Grote; Wolfgang Greiner; Germaine Hanquet; Raymond Hutubessy; Mark Jit; Mirjam Knol; Rüdiger von Kries; Alexander Kuhlmann; Daniel Levy-Bruhl; Matthias Perleth; Maarten Postma; Heini Salo; Uwe Siebert; Jürgen Wasem; Ole Wichmann
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

4.  Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice.

Authors:  James F O'Mahony; Anthony T Newall; Joost van Rosmalen
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

Review 5.  Economic evaluations of vaccines in Canada: a scoping review.

Authors:  Ellen R S Rafferty; Heather L Gagnon; Marwa Farag; Cheryl L Waldner
Journal:  Cost Eff Resour Alloc       Date:  2017-05-05

6.  How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations.

Authors:  Frank Sandmann; Mary Ramsay; W John Edmunds; Yoon H Choi; Mark Jit
Journal:  Value Health       Date:  2021-07-30       Impact factor: 5.101

7.  Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?

Authors:  Mark Jit; Raymond Hutubessy
Journal:  Appl Health Econ Health Policy       Date:  2016-06       Impact factor: 2.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.